Novavax Gains US FDA Advisory Committee Endorsement, But So Does Myocarditis Risk Statement

Vaccines and Related Biological Products Advisory Committee members agree another option should be made available, especially if Novavax's protein-based design could encourage those who refused the mRNA vaccines to be inoculated.

FDA vaccines advisory committee meeting screenshot
The Vaccines and Related Biological Products Advisory Committee vote on the Novavax COVID-19 vaccine is announced during the 7 June meeting. • Source: Screenshot

Novavax, Inc.’s proposed COVID-19 vaccine easily cruised to a favorable recommendation for emergency use authorization from the US Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee, but a warning about a risk of myocarditis also seems inevitable.

The committee voted 21-0 with one abstention on 7 June that the benefits of the vaccine outweigh the risks and...

More from US FDA Performance Tracker

America Next: Most Novel Agents With July Goal Dates Have Been Approved Overseas

 

The US FDA will not be in its usual position as the first regulator to approve novel drugs, with only one of the six novel candidates on the July user fee calendar seeking its first approval worldwide in the US

US FDA’s June Approval Forecast: Infection Prevention, Cancer And HAE

 

Upcoming FDA user fee goal dates include novel products from a busy lung cancer pipeline, a single-dose passive immunization against RSV for infants, what could be the first oral HAE acute treatment, and a first-in-class HAE preventive antibody.

Keep Talking: US FDA’s Beleaguered Biologics Center Remains Vital To Regenerative Medicine

 

Advisory committee for Capricor’s deriamocel planned, regenerative medicine advanced therapy designations proliferate for osteoarthritis, and the ranks of dual RMAT/breakthrough therapy designation holders grow.

Maybe In May: US FDA Calls Coming On Moderna Next-Gen COVID-19 Vaccine, AbbVie’s Big ADC Bet

 

The 31 May goal date for Moderna’s next-generation COVID-19 vaccine looms over the month, but the US FDA's decision lineup includes three more novel agents, including AbbVie's Teliso-V antibody-drug conjugate, as well as supplemental indications like GSK's bid for Nucala in COPD.

More from Regulatory Trackers